Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―-Reference-Cited by-同舟云学术

Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism　― Subanalysis of the J’xactly Study ―

Published:2023-04-10 Issue:4 Volume:5 Page:144-151
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Nakamura Mashio¹,Fukuda Ikuo²,Yamada Norikazu³,Takayama Morimasa⁴,Maeda Hideaki⁵,Yamashita Takeshi⁶,Ikeda Takanori⁷,Mo Makoto⁸,Yamazaki Tsutomu⁹,Okumura Yasuo¹⁰,Hirayama Atsushi¹¹,

Affiliation:

1. Nakamura Medical Clinic

2. Department of Cardiology, Keimeikai Yokawa Hospital

3. Department of Cardiology, Kuwana City Medical Center

4. Department of Cardiology, Sakakibara Heart Institute

5. Department of Heart and Vascular Center, Ukima Central Hospital

6. Department of Cardiovascular Medicine, The Cardiovascular Institute

7. Department of Cardiovascular Medicine, Toho University Faculty of Medicine

8. Department of Cardiovascular Surgery, Yokohama Minami Kyosai Hospital

9. Innovation and Research Support Center, International University of Health and Welfare

10. Division of Cardiology, Department of Medicine, Nihon University School of Medicine

11. Department of Cardiology, Osaka Police Hospital

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/5/4/5_CR-23-0008/_pdf

Reference17 articles.

1. 1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: A major contributor to the global disease burden. J Thromb Haemost 2014; 12: 1580–1590.

2. 2. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet 2021; 398: 64–77.

3. 3. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: Chest guideline and expert panel report. Chest 2016; 149: 315–352.

4. 4. Nakamura M, Yamada N, Ito M. Novel anticoagulant therapy of venous thromboembolism: Current status and future directions. Ann Vasc Dis 2017; 10: 92–98.

5. 5. EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.